An evaluation of lithium as an adjunct to carbimazole treatment in acute thyrotoxicosis.
Article Details
- CitationCopy to clipboard
Turner JG, Brownlie BE, Sadler WA, Jensen CH
An evaluation of lithium as an adjunct to carbimazole treatment in acute thyrotoxicosis.
Acta Endocrinol (Copenh). 1976 Sep;83(1):86-92.
- PubMed ID
- 989225 [ View in PubMed]
- Abstract
The rate of control of thyrotoxicosis during the first 2 weeks of treatment was documented in 63 patients. Twenty-three patients received carbimazole 40 mg plus lithium carbonate 750 mg daily and a comparable group of 20 patients were given carbimazole 40 mg plus potassium iodide 120 mg daily. In the lithium treated patients the mean percentage fall of serum T4 after 2 weeks treatment was 49% and the fall in serum T3 57%. The results were similar in the iodide treated patients; the mean falls in serum T4 and T3 being 47% and 64%, respectively. Serum lithium values varied between 0.1-1.25 mEq./l; lithium side effects were minor. In a companion study 20 patients were treated with carbimazole alone. The responses in this group were less impressive; the mean falls in serum T4 and T3 at 2 weeks being 18% and 36%, respectively. It is concluded that lithium is a safe adjunct to conventional antithyroid drug therapy in the initial treatment of acute thyrotoxicosis.
DrugBank Data that Cites this Article
- Pharmaco-metabolomics
Drug Drug Groups Metabolite Change Description Carbimazole Approved Investigational T4 decreased Carbimazole decreases the level of T4 in the blood Carbimazole Approved Investigational T3 decreased Carbimazole decreases the level of T3 in the blood Iodide Approved Experimental T4 decreased Iodide decreases the level of T4 in the blood Iodide Approved Experimental T3 decreased Iodide decreases the level of T3 in the blood Lithium cation Experimental T4 decreased Lithium cation decreases the level of T4 in the blood Lithium cation Experimental T3 decreased Lithium cation decreases the level of T3 in the blood